Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Dawson James Downgrades Kintara Therapeutics to Neutral

Dawson James analyst Jason Kolbert downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Neutral.
byBenzinga Newsdesk
May 16, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Dawson James analyst Jason Kolbert downgrades Kintara Therapeutics (NASDAQ:KTRA) from Buy to Neutral.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0